Aa
Good news In case you have not heard Bristol Myers is
Good news In case you have not heard Bristol Myers is filing in japan for first oral treatment for genotype one .
We are not in Japan but still good news as I think Gilead and Abbvie will push harder to release there products faster , big companies and money talks .
Also this is good I think because if it was only Gilead in this race , the price of the there treatment would be extremely expensive as Gilead are well known to be very expensive .
Abbvie , Bristol Myers and Gilead will price more fairly I believe now as there is huge market .
2014 should be a good year to many of us .
In the multibillion-dollar race to bring oral hepatitis C treatments to market, Bristol-Myers Squibb is leapfrogging Gilead Sciences and Johnson & Johnson by filing for approval for daclatasvir with Japan's Pharmaceutical and Medical Devices Agency.
The daclatasvir and asunaprevir combo therapy is the first all-oral treatment to be filed for approval, eliminating side-effect-riddled interferon and ribavirin. Bristol's strategic move to go for a Japan launch rather than battle Gilead's sofosbuvir and J&J's simeprevir in the United States is a dramatic shift for the industry and may mark a shift in global drug development toward Japan -- a country in the midst of redefining itself as R&D friendly.
We are not in Japan but still good news as I think Gilead and Abbvie will push harder to release there products faster , big companies and money talks .
Also this is good I think because if it was only Gilead in this race , the price of the there treatment would be extremely expensive as Gilead are well known to be very expensive .
Abbvie , Bristol Myers and Gilead will price more fairly I believe now as there is huge market .
2014 should be a good year to many of us .
In the multibillion-dollar race to bring oral hepatitis C treatments to market, Bristol-Myers Squibb is leapfrogging Gilead Sciences and Johnson & Johnson by filing for approval for daclatasvir with Japan's Pharmaceutical and Medical Devices Agency.
The daclatasvir and asunaprevir combo therapy is the first all-oral treatment to be filed for approval, eliminating side-effect-riddled interferon and ribavirin. Bristol's strategic move to go for a Japan launch rather than battle Gilead's sofosbuvir and J&J's simeprevir in the United States is a dramatic shift for the industry and may mark a shift in global drug development toward Japan -- a country in the midst of redefining itself as R&D friendly.
Profit motive for these companies is huge we are lucky they have competition prices will much more competitive and fair which will mean easier access with insurance companies , pbs , developing countries and so forth , if it was a one horse race prices prices would be ridiculous especially with gilead .
My opinion is that Abbvie and Gilead will be filing for fda sooner than many expect as this year just as sofosbuvir was filed earlier than many predicted , there is to much money at stake and money is there only motive .
My opinion is that Abbvie and Gilead will be filing for fda sooner than many expect as this year just as sofosbuvir was filed earlier than many predicted , there is to much money at stake and money is there only motive .
I think you make a good point. If it wasn't for the profit motive the companies wouldn't be competing so ferociously. If price is fixed or socialized down investors will invest elsewhere other than drug companies that create new drugs. Capitalism and competition save lives.
No dates but if we go by sofosbuvir and simeprevir which have already been fda approval in japan , then the Bristol myers all oral combo therapy good chance will be approved by about May 2014
Have an Answer?
You are reading content posted in the Hepatitis C Community
Learn about this treatable virus.
Getting tested for this viral infection.
3 key steps to getting on treatment.
4 steps to getting on therapy.
What you need to know about Hep C drugs.
How the drugs might affect you.
These tips may up your chances of a cure.
A list of national and international resources and hotlines to help connect you to needed health and medical services.
Herpes sores blister, then burst, scab and heal.
Herpes spreads by oral, vaginal and anal sex.
STIs are the most common cause of genital sores.
Condoms are the most effective way to prevent HIV and STDs.
PrEP is used by people with high risk to prevent HIV infection.
